Viewing Study NCT05815602



Ignite Creation Date: 2024-05-06 @ 6:52 PM
Last Modification Date: 2024-10-26 @ 2:56 PM
Study NCT ID: NCT05815602
Status: RECRUITING
Last Update Posted: 2023-05-11
First Post: 2023-04-04

Brief Title: Ebastine Versus Mebeverine in IBS Patients
Sponsor: Guy Boeckxstaens
Organization: KU Leuven

Study Overview

Official Title: Multicenter Randomized Controlled Clinical Trial Comparing Ebastine and Mebeverine as Treatment of Irritable Bowel Syndrome
Status: RECRUITING
Status Verified Date: 2024-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Multicenter randomized controlled clinical trial comparing ebastine and mebeverine as treatment of irritable bowel syndrome

Trial rationale

1 To perform a randomized superiority trial comparing the clinical efficacy of ebastine and mebeverine
2 To evaluate the impact of treatment with ebastine compared to mebeverine on quality of life and quality-adjusted life years

Primary objective To provide further evidence of the superiority of histamine 1 receptor antagonism as novel treatment for patients with non-constipated IBS as compared to mebeverine one of the spasmolytics currently used as first line treatment of IBS

Secondary objectives To provide evidence that the histamine 1 receptor antagonist ebastine is more effective in reducing abdominal pain compared to the commonly used antispasmodic mebeverine
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: None